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Abstract
Background: Vascular endothelial growth factor (VEGF)-C is implicated in lymphangiogenesis,
however the exact role of VEGF-C in promoting lymphatic spread of cancer cells remains largely
unknown.
Methods: The expression of VEGF-C was immunohistochemically determined in 97 endoscopic
biopsy specimens from 46 patients with submucosal gastric carcinoma (SGC). Nodal metastases
including micrometastasis and isolated tumor cells (ITC) were evaluated by immunohistochemical
staining for cytokeratin in 1650 lymph nodes, and tumor cells in these metastatic nodes were also
examined for VEGF-C expression.
Results: In biopsy samples, VEGF-C was positively detected in 21 (47%) patients. Metastases were
identified in 46 (2.8%) nodes from 15 (33%) patients. Metastases were detected in 39 nodes by
hematoxylin-eosin (H&E) staining and in additional 7 nodes as ITC by immunohistochemical
staining. The rate of lymph node metastases was significantly correlated with VEGF-C expression
in biopsy samples (p < 0.05). The positive and negative predictive values of VEGF-C in biopsy
specimens for nodal metastasis were 44 %(10/21) and 80% (20/25), respectively. Among the 46
metastatic nodes, tumor cells in 29 (63%) nodes positive patients expressed VEGF-C, whereas
those in 17 (37%) nodes did not. VEGF-C expression was high in macronodular foci in medullary
areas, whereas more than half of ITC or micrometastasis located in peripheral sinus lacked the
expression of VEGF-C.
Conclusions: Despite the significant correlation, immunodetcetion of VEGF-C in endoscopic
biopsy specimens could not accurately predict the nodal status, and thus cannot be applied for the
decision of the treatment for SGC. VEGF-C may not be essential for lymphatic transport, but
rather important to develop the macronodular lesion in metastatic nodes.
Background
The incidence of early gastric carcinoma defined as being
confined to the mucosa or submucosal layer has
increased. In Japan, endoscopic mucosal resection (EMR)
is now generally accepted for intramucosal cancers that
are associated with a minimal risk of regional lymph node
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(LN) metastasis [1-4]. For submucosal gastric carcinoma
(SGC), however, conventional gastrectomy with complete
lymph node dissection has been performed as standard
treatment as the frequency of lymph node metastasis is
10–20%, which cannot be ignored clinically [5-8]. This
indicates that the conventional operative procedure pro-
vides no benefit for the majority of patients with SGC, and
thus criteria to safely avoid unnecessary lymphadenec-
tomy for submucosal cancer need to be determined.
VECF-C is known to bind VEGFR-3, which is specifically
expressed on lymphatic vessels and stimulates lymphang-
iogenesis [9,10]. Many previous reports have shown that
expression of VEGF-C in cancer tissues has a positive cor-
relation with the risk of lymphatic metastasis in breast
[11,12], lung [13], colorectal [14-17], pancreatic [18],
prostate [19], esophageal [14,20] and head and neck can-
cers [21,22]. A similar tendency has been reported for gas-
tric cancer, although a significant correlation between
VEGF-C expression and the frequency of nodal metastasis
is not always found [23-27].
Recently, small metastatic lesions have been detected
genetically or immunohistochemically in various cancers,
even though they were diagnosed as negative by conven-
tional examination with H&E staining. Such lesions are
designated as micrometastasis or isolated tumor cells
(ITC). The biological and clinical significance of such
minute nodal invasion of carcinoma cells is still contro-
versial [28-38]. In this study we performed immunohisto-
chemical staining and extensively examined VEGF-C
expression in biopsy samples and metastatic lymph nodes
including micrometastasis and ITC. From these data, we
attempted to determine whether the detection of VEGF-C
in biopsy samples could be a clinical predictor of accurate
nodal status in SGC. Then, we discussed how the VEGF-C
expressed in tumor cells functions in the metastatic proc-
ess to regional lymph nodes.
Patients and methods
Forty-six patients with SGC diagnosed and treated by cur-
ative gastrectomy with standard lymph node dissection at
the First Department of Surgery, Tokyo University Hospi-
tal, Tokyo, between 1994 and 2002 were included in this
study. These patients were examined endoscopically prior
to surgery; several pieces of tissue specimens were then
sampled with routine biopsy forceps from various por-
tions of the tumor. Formalin-fixed and paraffin-embed-
ded sections of 97 biopsy specimens and 1650 dissected
lymph nodes derived from these 46 patients were evalu-
ated in this study. Additionally, all the resected primary
tumors were histologically examined with H&E staining
according to the Japanese Classification of Gastric Carci-
noma [39]. Tumors were histologically classified into two
types based on the predominant features: differentiated
type (well and moderately differentiated adenocarci-
noma) and undifferentiated type (poorly differentiated
adenocarcinoma and signet ring cell carcinoma). Several
discrete histological parameters, including lymphatic
invasion, venous invasion and lymph node metastasis,
were also evaluated.
Immunohistochemical study of VEGF-C and Cytokeratin
The expression of VEGF-C was investigated with immuno-
histochemical staining using affinity purified goat poly-
clonal antibodies against VEGF-C (IBL, Fujioka, Japan).
Sections (3-µm thick) of biopsy samples were deparaffin-
ized in xylene, hydrated through a graded series of etha-
nol, and then immersed in 3% hydrogen peroxide in
100% methanol for 30 min to inhibit endogenous perox-
idase activity. To activate the antigens, the sections were
boiled in 10 mM citrate buffer, pH 6.0 for 30 minutes.
After being rinsed in phosphate-buffered saline (PBS), the
sections were incubated with normal rabbit serum for 10
min, and then incubated overnight at 4°C in humid
chambers with the primary antibody to VEGF-C at 1/30
dilution. After three washes with PBS, the sections were
incubated with biotinylated rabbit anti-goat immu-
noglobulin for 20 minute. After washing again with PBS,
the slides were treated with peroxidase-conjugated
streptavidin for 20 minutes, and developed by immersion
in 0.01% H2O2 and 0.05% diaminobenzidine tetrahydro-
chloride for 3 minute. Light counterstaining with Mayer's
hematoxylin was performed. The 46 lymph nodes that
showed the presence of carcinoma were also evaluated for
the expression of VEGF-C with the same immunostaining
method.
The dissected lymph nodes were fixed in 10% formalin
and embedded in paraffin. From each node, one 3-µm-
thick section was prepared for H&E staining, and another
three serial 5-µm sections were prepared for immunohis-
tochemical staining with CAM 5.2 (Becton Dickinson,
San Jose, CA), a mouse monoclonal antibody that reacts
with human cytokeratin numbers 8 and 18 [40]. The
streptavidin biotin immunoperoxidase technique was
used. Deparaffinized and rehydrated sections were
trypsinized with 1% calcium chloride solution at 37°C for
20 minutes. After nonspecific reactions were blocked with
10% normal rabbit serum, the sections were incubated
with CAM 5.2 diluted 1/6, biotinylated rabbit anti-mouse
immunoglobulin, and streptavidin peroxidase. Between
each two incubation steps, sections were washed carefully
in phosphate buffered saline.
Definition of lymph node metastasis
Metastasis was defined as the presence of tumor cells,
whether single or in small clusters detected by H&E or
immunohistochemical staining. Metastatic lesions that
were more than 2.0 mm in diameter were defined asWorld Journal of Surgical Oncology 2005, 3:2 http://www.wjso.com/content/3/1/2
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macrometastasis, while micrometastasis was defined as a
tumor deposit larger than 0.2 mm but less than 2.0 mm,
and ITC was defined as a tumor deposit less than 0.2 mm
in maximum diameter.
Statistical analysis
All statistical calculations were carried out using StatView-
J 5.0 statistical software (SAS Institute, USA). The relation-
ship between clinical and pathological characteristics of
patients and the expression of VEGF-C was examined by
Fisher's exact test. Differences with a p value of less than
0.05 were considered to be statistically significant.
Results
Nodal status including micrometastases and isolated 
tumor cells (ITC) in SGC
Metastases were observed in 12 patients (26.1%) and 39
lymph nodes (2.4%) by H&E examination (Fig. 1-c, f).
Among these nodes, cancer cells were detected as
micrometastasis (less than 2.0 mm) in 5 lymph nodes and
as ITC (less than 0.2 mm) in another 5 nodes. By immu-
nohistochemical staining with anti-cytokeratin antibody,
we additionally identified such small metastatic lesions in
7 nodes (Fig. 1-d, g). All of the 7 metastatic lesions were
categorized as ITC. Four nodes were derived from 4
patients who had other metastatic nodes detected by H&E
staining. Cytokeratin-positive cells were also identified in
other 3 nodes from 3 patients who showed no metastatic
nodes by H&E staining and were diagnosed as node nega-
tive cases. Thus, the final frequency of lymph node metas-
tasis increased to 15 of 46 patients (33%) and 46 of 1650
lymph nodes (2.8%).
Table 1 show the relationship between the exact nodal sta-
tus and other clinical/pathological features. Metastases
were frequently observed in tumors with deep submu-
cosal invasion or lymphatic involvement, which were
consistent with previous reports.
Immunohistochemical analysis of VEGF-C in biopsy and 
surgical specimens
The biopsy specimens were divided into two categories by
the staining pattern of VEGF-C, diffuse or focal staining of
carcinoma cells as described previously [26]. When dis-
tinct staining of the cytoplasm was observed in the major-
ity of tumor cells, whether diffuse or focal, these samples
were categorized as VEGF-C positive in this study (Fig. 1-
a). Whereas other cases in which only a few carcinoma
Immunohistochemical staining of VEGF-C in biopsied speci- mens (upper panel) and hematoxylin-eosin (H&E) staining,  immunohistochemical staining of cytokeratin and VEGF-C in  metastastic lymph node (middle and lower panel) Figure 1
Immunohistochemical staining of VEGF-C in biopsied speci-
mens (upper panel) and hematoxylin-eosin (H&E) staining, 
immunohistochemical staining of cytokeratin and VEGF-C in 
metastastic lymph node (middle and lower panel). a, VEGF-C 
positive type in biopsied specimens. b, VEGF-C negative type 
in biopsied specimens. c, f, hematoxylin-eosin (H&E) staining 
in metastastic lymph node. d, g, immunohistochemical stain-
ing of cytokeratin in metastastic lymph node. e, VEGF-C pos-
itive type in metastastic lymph node. h, VEGF-C negative type 
in metastastic lymph node.
Table 1: Nodal metastasis, including nicrometastasis/ITC and 
clinical and/or pathological findings
Patients with lymph node metastasis
positive(15) negative(31) p value
Age
60< 6 16
<59 9 15 0.46
Sex
Male 11 22
Female 4 9 0.87
Tumor size (cm)
3.0< 11 19
2.9> 4 12 0.42
Macroscopic type
elevated 2 1
depressed 13 30 0.19
Depth of invasion
sm1 3 18
sm2,3 12 13 0.02
Histological type
differentiated 8 14
undifferentiated 7 17 0.6
Lymphatic involvement
positive 4 2
negative 11 29 0.05
Venous involvement
positive 2 2
negative 13 29 0.44World Journal of Surgical Oncology 2005, 3:2 http://www.wjso.com/content/3/1/2
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Table 3: The location of tumor cells in metastatic nodes and VEGF-C expression in 15 node positive patients.
Case VEGF-C expression definition of 
metastasis**
Detection method* location of tumor 
cells
biopsy specimens# metastatic nodes
1 - - ITC H.E. marginal
2 - + macrometastasis H.E. medullary
+I T C H . E . m a r g i n a l
+ macrometastasis H.E. medullary
3 - - macrometastasis H.E. marginal
- macrometastasis H.E. marginal
- ITC I.H.C. marginal
4 - - macrometastasis H.E. marginal
- macrometastasis H.E. marginal
5 + + + macrometastasis H.E. marginal
- macrometastasis H.E. marginal
- macrometastasis H.E. marginal
6 + + macrometastasis H.E. medullary
+ macrometastasis H.E. medullary
+ macrometastasis H.E. medullary
+ macrometastasis H.E. medullary
+ macrometastasis H.E. medullary
- ITC I.H.C. marginal
7 + + micrometastasis H.E. medullary
+I T C H . E . m a r g i n a l
+I T C H . E . m a r g i n a l
8 + + + macrometastasis H.E. medullary
+ macrometastasis H.E. medullary
+ macrometastasis H.E. medullary
+ micrometastasis H.E. medullary
+ micrometastasis H.E. medullary
9 + - ITC H.E. marginal
- ITC I.H.C. marginal
10 + + - micrometastasis H.E. marginal
11 + + + + macrometastasis H.E. medullary
- micrometastasis H.E. medullary
- ITC I.H.C. marginal
12 + + + + macrometastasis H.E. medullary
+ macrometastasis H.E. medullary
+ macrometastasis H.E. medullary
+ macrometastasis H.E. medullary
+ macrometastasis H.E. medullary
+ macrometastasis H.E. medullary
+ macrometastasis H.E. medullary
+ macrometastasis H.E. medullary
+ macrometastasis H.E. medullary
+ macrometastasis H.E. medullary
+ macrometastasis H.E. medullary
13 - - ITC I.H.C. marginal
14 + + - ITC I.H.C. marginal
15 + - ITC I.H.C. marginal
*:IHC means immunohistochemical staining with anti-cytochelatin mAb.
**:Micrometastasis is defined as tumor deposit larger than 0.2 mm but less than 2.0 mm, and ITC (isolated tumor cell) is defined as tumor deposit 
less than 0.2 mm in the maximum diameter. Larger deposits were classified as macrometastasis.
#: The number of +/- means the number of examined biopsy specimens obtained from different parts of the tumor.World Journal of Surgical Oncology 2005, 3:2 http://www.wjso.com/content/3/1/2
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cells stained faintly were classified as VEGF-C negative
(Fig. 1-b).
Among the 97 biopsy samples from 46 patients, carci-
noma cells were contained in only one biopsy sample in
14 patients, and in 2, 3 and 4 biopsy samples in 16, 13
and 3 patients, respectively. In all of the latter cases, carci-
noma cells in biopsy samples derived from different
places showed exactly the same staining pattern of VEGF-
C, and thus VEGF-C-positive and -negative tumors could
be clearly distinguished.
In biopsy specimens, VEGF-C was positively detected in
21 (46%) cases. As shown in Table 1, the expression of
VEGF-C in biopsy samples showed a significant correla-
tion with that in surgically removed specimens (p =
0.005). However, 15 (60%) of 25 cases that were classi-
fied as VEGF-C negative in biopsy samples showed posi-
tive expression of VEGF-C in surgical specimens. In
contrast, 20 of 21 cases with VEGF-C-positive biopsy sam-
ples also expressed VEGF-C in surgical specimens, indicat-
ing that positive expression of VEGF-C was mostly
consistent between biopsy and surgical specimens. Thus,
the immunodetection of VEGF-C in biopsy sample
showed 95% of positive predictive value and 40% of neg-
ative predictive values for VEGF-C expression in primary
tumor.
Immunohistochemical detection of VEGF-C in biopsy 
specimens
Nodal metastasis was detected in 10 (48%) of 21 VEGF-C-
positive tumors, and the rate was significantly higher than
that in VEGF-C-negative tumors as evaluated by biopsy
specimens (5/25, 20%) (p = 0.047). However, the positive
and negative predictive values of VEGF-C in biopsy for
nodal status were 44% (10/21) and 75% (20/25), respec-
tively, and 5 (20%) of 25 VEGF-C-negative tumors were
accompanied with lymph node metastasis.
Expression of VEGF-C in tumor cells in metastatic lymph 
nodes
Table 3 shows the expression pattern of VEGF-C of tumor
cells in 46 metastatic lymph nodes as well as in 23 biopsy
samples in 15 patients. Interestingly, the expression of
VEGF-C in metastatic tumor cells in lymph nodes was not
necessarily correlated with that in biopsy samples. In 15
cases with nodal metastasis, VEGF-C was positively
detected in 18 biopsy samples from 10 (67%) patients.
On the other hand, VEGF-C was positive in metastatic
tumor cells in 29 nodes derived from 7 (47%) patients
(Fig. 1-e), while tumor cells metastasized in 17 (37%)
lymph nodes derived from 11 (73%) patients were nega-
tive for VEGF-C (Fig. 1-h).
Among 36 nodes from 10 patients who were determined
as VEGF-C-positive in biopsy samples, tumor cells located
in 10 (29%) nodes from 4 (40%) patients totally lacked
the expression of VEGF-C. This finding clearly indicates
that carcinoma cells that highly express VEGF-C are not
always preferentially transported to the regional lymph
nodes, even though the expression of this
lymphangiogenic factor had a positive correlation with
lymph node metastasis.
More interestingly, the expression of VEGF-C was strongly
correlated with the size of metastatic foci and the location
of carcinoma cells in metastatic nodes (Table 3). When
carcinoma cells invaded the medullary area of lymph
nodes, most of the tumor cells positively expressed VEGF-
C (25/26, 96%). In contrast, the rate of VEGF-C-positive
cells was markedly lower (4/20, 20%), when the carci-
noma cells remained in the peripheral area of lymph
nodes. Also, 22 (79%) of 28 macrometastases expressed
VEGF-C, while 3 (60%) of 5 micrometastases and only 3
(25%) of 12 ITC were positive for VEGF-C. It is especially
notable that all of the 7 ITC detected by immunostaining
lacked expression of VEGF-C.
Discussion
Many cancers metastasize to regional lymph nodes, and a
positive nodal status often correlates with a poor progno-
sis of patients. However, the mechanisms of lymphatic
metastasis have not been investigated in detail. Recent
studies have demonstrated that the expression of VEGF-C
is enhanced in various solid tumors, suggesting the possi-
ble contribution of VEGF-C to nodal metastasis, possibly
through lymphangiogenesis [41,42]. Number of clinical
studies has shown a positive correlation between VEGF-C
expression and risk of lymph node metastasis in various
cancers including gastric cancer [11,12]. However, all of
the data were obtained in surgically resected specimens,
and thus can not be used for preoperative information to
determine the treatment.
In this study, therefore, we evaluated the expression of
VEGF-C in biopsy samples in SGC. Our initial hypothesis
was that VEGF-C expression can predict the accurate nodal
status including micrometastasis/ITC, and thus may be
useful to avoid the unnecessary gastrectomy in some SGC.
Our results suggest that VEGF-C expression in biopsy
specimens correlate with lymph node metastasis in SGC.
However, the positive and negative predictive values were
44% and 80% respectively, and 20% of VEGF-C-negative
tumors were node positive. This suggests that the immun-
odetection of VEGF-C in biopsy samples can not be used
as clinical indicator to decide the treatment of SGC.
Present study provides some interesting findings on the
possible role of VEGF-C in nodal metastasis. Biopsy sam-World Journal of Surgical Oncology 2005, 3:2 http://www.wjso.com/content/3/1/2
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ples were obtained at preoperative endoscopy, fixed with
formalin immediately after biopsy, and thus appear to
reflect the in situ expression level of VEGF-C more pre-
cisely than surgically resected specimens. In our results,
VEGF-C expression in biopsy samples showed a signifi-
cant correlation with that in surgical specimens with 57%
sensitivity and 91% specificity. However, more than half
(60%) of the tumors categorized as VEGF-C negative in
biopsy specimens were positive in surgical specimens,
although VEGF-C-positive tumors in biopsy samples
showed a good consistency with those in surgical speci-
mens. This raises the possibility that VEGF-C expression
may be somewhat upregulated by surgical manipulation.
VEGF gene expression is regulated by a variety of stimuli,
and hypoxia is known to be one of the most potent induc-
ers of VEGF-A [43,44]. VEGF-C expression has also been
reported to be enhanced by hypoxia in some reports
[45,46], but not in others [47,48]. Although the detailed
regulatory mechanisms of VEGF-C gene activation are not
well understood, our results suggest a possibility that
VEGF-C in surgical specimen may be induced by hypoxia
during gastrectomy at least in some cases. This point
should be included for the evaluation of the results in
previous studies showing the positive correlation with
nodal status.
Nonetheless, our data showed a significant correlation of
VEGF-C expression in biopsy specimens with nodal
metastasis, supporting a possible role of VEGF-C in lym-
phatic metastasis. As with hematogeneous metastasis,
lymphatic metastasis of cancer cells is considered to be
divided into several steps: invasion to lymphatic capillar-
ies, movement into the lymphatic lumen with the lym-
phatic stream, attachment to the subcapsular sinus of
lymph nodes, and invasion into the cortex. Lymphangio-
genesis means the development and proliferation of new
lymphatics from host vessels, but the ability of tumor cells
to induce lymphangiogenesis and the presence of intratu-
moral lymphatic vessels are controversial. However, most
malignant tumors are known to be associated with an
increased number of lymphatic vessels in the peripheral
area [42]. In fact, in vivo experiments using VEGF-C-trans-
fected tumors have shown the same histological findings
[49,50]. Since intratumoral interstitial fluid pressure is
known to be higher than that in normal tissues, the
hydrostatic pressure difference appears to transport the
tumor cells from inside of the tumor to the peritumoral
area. Therefore, the metastasis-promoting effect has been
attributed to an increase and dilatation of peritumoral
lymphatic capillaries. VEGF-C may facilitate metastasis by
increasing the surface area of lymphatic vessels in contact
with interstitial tumor cells in the area around the primary
tumor site, and thus increase the chance of these cells
entering the lymphatic system.
In regional lymph nodes, tumor cells are thought to reach
the peripheral sinus from afferent lymphatics. In fact,
many metastatic cells were detected around the sinus area
unless they developed into a macronodular lesion.
Recently, small lesions have been divided into two catego-
ries; micrometastasis and isolated tumor cells (ITC),
which are distinguished based on their size [51].
Micrometastasis is defined as a tumor deposit larger than
0.2 mm but less than 2.0 mm, while ITC is defined as a
tumor deposit less than 0.2 mm in maximum diameter.
Although the biological features of these categories have
not been fully clarified, they are now pathologically
defined as pN1m1 and pN0, respectively.
In our study, the metastatic lesions did not always express
VEGF-C, and such small metastatic foci often lacked the
expression of VEGF-C. Especially, ITC identified only with
immunohistochemical staining are totally negative for
VEGF-C. In addition, in 4 tumors with lymphatic inva-
sion, none of the tumor cells located in the lymphatic ves-
sels in the primary tumor expressed VEGF-C (data not
presented). These unexpected results suggest that expres-
sion of VEGF-C in tumor cells is not relevant to the
transportation to regional nodes once they enter lym-
phatic vessels.
In contrast, most of the macrometastases or cancer cells
invading the medullary area of metastatic nodes highly
expressed VEGF-C. This phenomenon was quite interest-
ing, though not fully explained by today's knowledge.
This may suggest that proliferation and invasion in the
internal area of metastatic nodes may partially require
VEGF-C expression in tumor cells. Thus far, there is no
definite report on the effects of VEGF-C on tumor cells.
The VEGF-receptor 3 (VEGFR-3), a specific ligand of
VEGF-C, was expressed only on certain tumor cells [52-
54] and not on others. We tried to examine the expression
of VEGF-C receptor in these gastric cancers using a poly-
clonal antibody to VEGFR-3, but could not detect positive
staining in any case (data not shown). Thus, it seems to be
unlikely that VEGF-C directly affects the behavior of gas-
tric cancer cells. However, it remains a possibility that
VEGF-C secreted from tumor cells may act on intranodal
lymphatic endothelial cells or other interstitial cells and
create favorable conditions for tumor cell growth or inva-
sion in lymph nodes.
In summary, our retrospective study demonstrated that
VEGF-C expression in tumor cells in biopsy specimens
was significantly correlated with lymphatic metastasis in
SGC, although the accuracy was not high enough to be
used for clinical indicator. Metastatic tumor cells in
micrometastasis or ITC located in marginal sinus often
lacked the expression of VEGF-C, whereas macrometasta-
sis located in the medullary area in metastatic nodesWorld Journal of Surgical Oncology 2005, 3:2 http://www.wjso.com/content/3/1/2
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highly express VEGF-C. This suggests a possibility that
expression of VEGF-C is not essential for lymphatic trans-
port from primary tumor, but rather important to develop
the macronodular lesion in metastatic lymph nodes.
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